ArticleHuman vaccines & immunotherapeutics2017
Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Trial
- The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Trial
- Epidemiologic and economic impact of introducing a National Immunization Program for herpes zoster vaccination on the prevention of herpes zoster and postherpetic neuralgia in South Korea, an ageing society.Epidemiology and infection · 2026Article
- Herpes Zoster in Aging Patients: Risk Factors and Prevention Strategies.International journal of general medicine · 2026Review
- Herpes zoster in older adults: Impact on carbon footprint in the United States.Human vaccines & immunotherapeutics · 2024Article
- The Incidence of Herpes Zoster Complications: A Systematic Literature Review.Infectious diseases and therapy · 2024Review
- Burden of Herpes Zoster Among Patients with Psoriasis in the United States.Dermatology and therapy · 2023Article
- Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States.Crohn's & colitis 360 · 2023Article
- Systematic Literature Review of Herpes Zoster Disease Burden in Southeast Asia.Infectious diseases and therapy · 2023Review
- The Endogenous Cannabinoid and the Nitricoxidergic Systems in the Modulation of Stress Responses.International journal of molecular sciences · 2023Article
- Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination.Human vaccines & immunotherapeutics · 2022Article
- Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis.Diabetes care · 2022Article
- Association of asthma and herpes zoster, the role of vaccination: A literature review.Immunity, inflammation and disease · 2022Review
- A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation.Plants (Basel, Switzerland) · 2022Review
- Comparison of Japanese Centenarians' and Noncentenarians' Medical Expenditures in the Last Year of Life.JAMA network open · 2021Article
- Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy Subjects.Journal of pain research · 2021Article
- Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.Journal of managed care & specialty pharmacy · 2020Article
- Patient and economic burdens of postherpetic neuralgia in China.ClinicoEconomics and outcomes research : CEOR · 2019Article
- The Economic Impact of Herpes Zoster Vaccine Disparities in Elderly United States Blacks.International journal of environmental research and public health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few peer-reviewed publications present real-world United States (US) data describing resource utilization and costs associated with herpes zoster (HZ) and postherpetic neuralgia (PHN). The primary objective of this analysis (GSK study identifier: HO-14-14270) was to assess direct costs associated with HZ and PHN in the US using a retrospective managed care insurance claims database. Patients ≥ 50 y at HZ diagnosis were selected. Patients were excluded if they were immunocompromised before diagnosis or received an HZ vaccine at any time. A subsample of patients with PHN was identified. Each patient with HZ was matched to ≤ 4 controls without HZ based on age, sex, and health plan enrollment. Incremental differences in mean HZ-related costs ("incremental costs") were assessed overall and stratified by age. Multivariable regression models controlled for the effect of demographic characteristics, prediagnosis costs, and comorbidity burden on costs using a recycled predictions approach. Overall, 142,519 patients with HZ (9,470 patients [6.6%] had PHN) and 357,907 matched controls without HZ were identified. Resource utilization was greater among patients with HZ than controls. After adjusting for demographic and clinical characteristics, annual incremental health care costs for HZ patients vs. controls were $1,210 for patients aged 50-59 years, $1,629 for those 60-64 years, $1,876 for those 65-69 years, $2,643 for those 70-79 years, and $3,804 for those 80+ years; adjusted annual incremental costs among PHN patients vs. controls were $4,670 for patients 50-59 years, $6,133 for those 60-64 years, $6,451 for those 65-69 years, $8,548 for those 70-79 years, and $11,147 for those 80+ years. HZ is associated with a significant cost burden, which increases with advancing patient age. Vaccination may reduce costs associated with HZ through case avoidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.